vs
Side-by-side financial comparison of Protagonist Therapeutics, Inc (PTGX) and Westrock Coffee Co (WEST). Click either name above to swap in a different company.
Westrock Coffee Co is the larger business by last-quarter revenue ($339.5M vs $170.6M, roughly 2.0× Protagonist Therapeutics, Inc). Protagonist Therapeutics, Inc runs the higher net margin — 77.2% vs -6.6%, a 83.8% gap on every dollar of revenue. On growth, Protagonist Therapeutics, Inc posted the faster year-over-year revenue change (184.4% vs 48.3%). Protagonist Therapeutics, Inc produced more free cash flow last quarter ($182.8M vs $27.8M).
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel peptide-based targeted therapies for unmet medical needs, primarily covering gastrointestinal disorders, inflammatory diseases and rare disease indications. Its lead product candidates target inflammatory bowel disease and other chronic immune-related conditions, with operations spanning global R&D and partnership collaborations.
Westrock Coffee Co is a global integrated coffee, tea and functional beverage solutions provider. It sources, roasts, manufactures and distributes coffee products, ready-to-drink beverages and custom formulations for retail, foodservice and commercial clients across North America and other key markets.
PTGX vs WEST — Head-to-Head
Income Statement — Q4 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $170.6M | $339.5M |
| Net Profit | $131.7M | $-22.6M |
| Gross Margin | — | 11.5% |
| Operating Margin | 74.3% | -2.6% |
| Net Margin | 77.2% | -6.6% |
| Revenue YoY | 184.4% | 48.3% |
| Net Profit YoY | 381.7% | 8.3% |
| EPS (diluted) | $2.01 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $339.5M | ||
| Q3 25 | — | $354.8M | ||
| Q2 25 | — | $280.9M | ||
| Q1 25 | — | $213.8M | ||
| Q4 24 | $170.6M | $229.0M | ||
| Q3 24 | — | $220.9M | ||
| Q2 24 | — | $208.4M | ||
| Q1 24 | $255.0M | $192.5M |
| Q4 25 | — | $-22.6M | ||
| Q3 25 | — | $-19.1M | ||
| Q2 25 | — | $-21.6M | ||
| Q1 25 | — | $-27.2M | ||
| Q4 24 | $131.7M | $-24.6M | ||
| Q3 24 | — | $-14.3M | ||
| Q2 24 | — | $-17.8M | ||
| Q1 24 | $207.3M | $-23.7M |
| Q4 25 | — | 11.5% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 14.7% | ||
| Q1 25 | — | 13.6% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | — | 16.8% | ||
| Q2 24 | — | 19.9% | ||
| Q1 24 | — | 19.4% |
| Q4 25 | — | -2.6% | ||
| Q3 25 | — | -2.4% | ||
| Q2 25 | — | -5.3% | ||
| Q1 25 | — | -6.1% | ||
| Q4 24 | 74.3% | -4.3% | ||
| Q3 24 | — | -5.8% | ||
| Q2 24 | — | -7.9% | ||
| Q1 24 | 80.9% | -5.3% |
| Q4 25 | — | -6.6% | ||
| Q3 25 | — | -5.4% | ||
| Q2 25 | — | -7.7% | ||
| Q1 25 | — | -12.7% | ||
| Q4 24 | 77.2% | -10.7% | ||
| Q3 24 | — | -6.5% | ||
| Q2 24 | — | -8.5% | ||
| Q1 24 | 81.3% | -12.3% |
| Q4 25 | — | $-0.22 | ||
| Q3 25 | — | $-0.20 | ||
| Q2 25 | — | $-0.23 | ||
| Q1 25 | — | $-0.29 | ||
| Q4 24 | $2.01 | $-0.26 | ||
| Q3 24 | — | $-0.16 | ||
| Q2 24 | — | $-0.20 | ||
| Q1 24 | $3.26 | $-0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $418.9M | $49.9M |
| Total DebtLower is stronger | — | $444.1M |
| Stockholders' EquityBook value | $675.3M | $-1.9M |
| Total Assets | $744.7M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $49.9M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $44.0M | ||
| Q1 25 | — | $33.1M | ||
| Q4 24 | $418.9M | $26.2M | ||
| Q3 24 | — | $22.4M | ||
| Q2 24 | — | $24.3M | ||
| Q1 24 | $322.6M | $12.6M |
| Q4 25 | — | $444.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $393.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $-1.9M | ||
| Q3 25 | — | $11.4M | ||
| Q2 25 | — | $18.2M | ||
| Q1 25 | — | $71.4M | ||
| Q4 24 | $675.3M | $97.5M | ||
| Q3 24 | — | $110.3M | ||
| Q2 24 | — | $81.5M | ||
| Q1 24 | $560.4M | $91.7M |
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $744.7M | $1.1B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | $629.3M | $983.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.03× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $184.2M | $36.7M |
| Free Cash FlowOCF − Capex | $182.8M | $27.8M |
| FCF MarginFCF / Revenue | 107.1% | 8.2% |
| Capex IntensityCapex / Revenue | 0.8% | 2.6% |
| Cash ConversionOCF / Net Profit | 1.40× | — |
| TTM Free Cash FlowTrailing 4 quarters | $101.7M | $-107.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $36.7M | ||
| Q3 25 | — | $-26.6M | ||
| Q2 25 | — | $-7.0M | ||
| Q1 25 | — | $-22.1M | ||
| Q4 24 | $184.2M | $2.8M | ||
| Q3 24 | — | $-332.0K | ||
| Q2 24 | — | $-23.7M | ||
| Q1 24 | $-27.4M | $8.0M |
| Q4 25 | — | $27.8M | ||
| Q3 25 | — | $-44.7M | ||
| Q2 25 | — | $-27.5M | ||
| Q1 25 | — | $-63.4M | ||
| Q4 24 | $182.8M | $-15.4M | ||
| Q3 24 | — | $-36.7M | ||
| Q2 24 | — | $-59.9M | ||
| Q1 24 | $-27.7M | $-60.9M |
| Q4 25 | — | 8.2% | ||
| Q3 25 | — | -12.6% | ||
| Q2 25 | — | -9.8% | ||
| Q1 25 | — | -29.7% | ||
| Q4 24 | 107.1% | -6.7% | ||
| Q3 24 | — | -16.6% | ||
| Q2 24 | — | -28.7% | ||
| Q1 24 | -10.9% | -31.7% |
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 5.1% | ||
| Q2 25 | — | 7.3% | ||
| Q1 25 | — | 19.3% | ||
| Q4 24 | 0.8% | 7.9% | ||
| Q3 24 | — | 16.5% | ||
| Q2 24 | — | 17.4% | ||
| Q1 24 | 0.1% | 35.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.40× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.13× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PTGX
Segment breakdown not available.
WEST
| Coffee And Tea | $202.6M | 60% |
| Flavors Extracts And Ingredients | $69.6M | 21% |
| Sustainable Sourcing And Traceability Segments | $66.9M | 20% |
